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Community-acquired diarrhoea in a world with rotavirus 
vaccine: a glimpse into the future
Diarrhoea remains a leading cause of morbidity and 
mortality in young children around the world, with 
more than half a million children dying every year 
from diarrhoeal diseases.1 In addition to its acute 
eﬀ ects, diarrhoea can contribute to malnutrition, 
growth retardation, and cognitive impairment. A 
multifaceted approach is needed to combat this public 
health problem, and a better understanding of speciﬁ c 
causative agents of diarrhoea will enable targeted 
prevention and treatment decisions.
In 2013, researchers from the Global Enteric 
Multicenter Study (GEMS)2 reported data from seven 
low-resource countries on the incidence, cause, and 
adverse outcomes of moderate-to-severe diarrhoea in 
children from birth to 59 months. The authors of GEMS 
conﬁ rmed the large burden of moderate-to-severe 
diarrhoea and reported a signiﬁ cant association with 
linear growth faltering and death in the selected low-
resource settings. Rotavirus was, unequivocally, the 
most common cause of moderate-to-severe diarrhoea 
in the ﬁ rst 2 years of life, while other pathogens, such 
as Cryptosporidium spp and heat-stable toxin-producing 
enterotoxigenic Escherichia coli (ST-ETEC), contributed 
signiﬁ cantly to mortality.3 
In this issue of The Lancet Global Health, James Platts-Mills 
and colleagues4 describe causes of diarrhoeal illness in 
the Mal-ED study. By contrast with GEMS, which sought 
to characterise the diarrhoeal episodes most likely to 
contribute to childhood mortality—that is, moderate-
to-severe diarrhoeal disease in children seeking care at 
health-care facilities—researchers in the Mal-ED study 
undertook intense community surveillance to record 
diarrhoea of any severity in the ﬁ rst 2 years of life. 
Eight sites in South America, Africa, and Asia 
participated in the study. Investigators collected 
diarrhoeal and non-diarrhoeal stools in order to calculate 
the adjusted attributable fraction to estimate pathogen-
speciﬁ c burdens of diarrhoea. The study was impressive 
in the heterogeneity of sites, the completeness of sample 
collection, and the comprehensiveness of stool testing.
The pathogens most often associated with diarrhoea, 
in order of importance, were norovirus GII, rotavirus, 
and Campylobacter spp in children younger than 1 year, 
and Campylobacter spp, norovirus GII, and rotavirus in 
children aged 1–2 years, although there was considerable 
variation between sites. As with the GEMS study, several 
agents were commonly isolated but not associated with 
diarrhoea, including Giardia and enteroaggregative E coli.
The Mal-ED results further emphasise the importance 
of rotavirus as a cause of severe diarrhoea—rotavirus 
was the pathogen most often associated with severe 
diarrhoeal episodes in the ﬁ rst and second years of 
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life. The eﬀ ect of rotavirus vaccination on ﬁ ndings was 
evident. In the ﬁ ves sites where rotavirus vaccines had 
not yet been introduced, rotavirus had the highest 
overall attributable fraction, whereas in the three sites 
where rotavirus vaccination had been introduced, 
rotavirus had only the ﬁ fth highest attributable 
fraction. Remarkably, in South Africa and Brazil, two 
countries that have introduced rotavirus vaccines, 
rotavirus was either not detected or not associated with 
diarrhoea in the ﬁ rst year of life. In Peru, the third site 
in the study to have introduced rotavirus vaccine, the 
attributable fraction was only 1·0 (95% CI 0·0–1·6) in 
the ﬁ rst year of life.
WHO has recommended rotavirus vaccines for all 
children since 2009.5 The good news is that, as of 
July 1, 2015, 77 countries, including 35 eligible for 
support from GAVI, have introduced rotavirus vaccines 
into their national immunisation programmes (ﬁ gure).6 
Studies to directly compare disease burden before and 
after vaccine introduction are already underway in Africa. 
Unfortunately, millions of children live in countries that 
have not yet included rotavirus vaccines in their national 
immunisation programmes. Platt-Mills and colleagues’ 
results4 should provide additional imptetus for the 
remaining countries to introduce rotavirus vaccines, 
particularly those in sub-Saharan Africa and southeast 
Asia, where more than 80% of the rotavirus deaths in 
children under 5 years occur.
The introduction of rotavirus vaccines would be 
expected to lead to changes in the relative importance 
of other pathogens as causes of clinically important 
diarrhoea. For example, in the USA and some middle-
income countries with the rotavirus vaccine, norovirus has 
replaced rotavirus as the most common agent identiﬁ ed 
in children hospitalised with acute gastroenteritis.7,8 In 
the Mal-ED study, Campylobacter spp had the strongest 
association with diarrhoea in the ﬁ rst year of life in all 
three sites where rotavirus vaccines had been introduced. 
Yet, Campylobacter spp were not a prominent cause 
of moderate-to-severe diarrhoea in the GEMS study. 
Thus, further studies are needed to determine the most 
common causes of severe diarrhoea in low-resource 
settings after the introduction of rotavirus vaccines to 
allow planning of the most eﬀ ective interventions to 
prevent and treat diarrhoeal illnesses in the future.
The increasing availability of molecular diagnostics 
promises higher detection rates of diarrhoeal 
pathogens, especially when antibiotic administration 
impedes identiﬁ cation of bacterial agents with 
traditional diagnostic techniques. Nevertheless, the 
substantial variation by location, severity and season 
in the pathogens isolated, and the large proportion 
of diarrhoeal episodes with no identiﬁ able causative 
agent, emphasises the need for generic, multifaceted 
approaches to the prevention and treatment of 
diarrhoeal diseases. The WHO/UNICEF Integrated 
Global Action Plan for the Prevention and Control of 
Pneumonia and Diarrhoea (GAPPD) addresses the critical 
need for coordinated and collaborative implementation 
of interventions.9 The plan advocates for accelerated 
eﬀ orts to decrease the incidence of diarrhoeal disease—
irrespective of the cause—through rotavirus vaccines, 
improved access to clean water, sanitation and hygiene, 
promotion of breastfeeding, and by improving access to 
zinc therapy and oral rehydration solution to improve 
health in the world’s most vulnerable children. 
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